{
    "pmcid": "8077567",
    "qa_pairs": {
        "What is the primary target for diagnostics and therapeutics in the study on sentinel cells and SARS-CoV-2?": [
            "The SARS-CoV-2 Spike protein",
            "The SARS-CoV-2 Nucleocapsid protein",
            "The SARS-CoV-2 Membrane protein",
            "The SARS-CoV-2 Envelope protein"
        ],
        "What platform is used to create customizable genetic responses upon antigen detection in the study?": [
            "SynNotch receptor system",
            "CRISPR-Cas9 system",
            "Toll-like receptor system",
            "Chimeric antigen receptor (CAR) system"
        ],
        "What potential application is highlighted for sentinel cells equipped with SARSNotch in the study?": [
            "Live cell therapies to detect and respond to viral infections",
            "Vaccination against SARS-CoV-2",
            "Gene editing of infected cells",
            "Production of viral antigens for diagnostics"
        ],
        "Which de novo-designed protein binder is used in the study to target the SARS-CoV-2 Spike protein?": [
            "LCB1",
            "ACE2",
            "LCB2",
            "RBD1"
        ],
        "Why were initial attempts using the ACE2 receptor as a sensor for the Spike protein less successful?": [
            "De novo-designed binders offer advantages in binding geometry and activation efficiency",
            "ACE2 receptors have low affinity for the Spike protein",
            "ACE2 receptors are not compatible with the SynNotch system",
            "ACE2 receptors are too large to be used in sentinel cells"
        ]
    }
}